Clinical Trial: A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title:
Brief Summary: To evaluate the efficacy of voloxicimab when administered at 15 mg/kg qwk in subjects with platinum-resistant, advanced epithelial ovarian cancer or primary peritoneal cancer.
Detailed Summary:
Sponsor: Facet Biotech
Current Primary Outcome: Efficacy as measured by objective response rate (ORR). Tumor response based on RECIST criteria. [ Time Frame: Baseline, and every 8 weeks on study ]
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Facet Biotech
Dates:
Date Received: August 14, 2007
Date Started: August 2007
Date Completion:
Last Updated: August 21, 2012
Last Verified: August 2012